{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:02:25Z","timestamp":1784905345624,"version":"3.55.0"},"reference-count":69,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tall Foundation Honours Scholarship in Pharmacy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Sci.","Medical Sciences"],"abstract":"<jats:p>Background: Concurrent use of acetylcholinesterase inhibitors (AChEIs) and medicines with anticholinergic activity is a clinically important medication safety concern in dementia care because these medicines may pharmacologically oppose dementia treatment and increase the risk of avoidable harm. This review systematically synthesised evidence on the prevalence, patterns, predictors and clinical consequences of concurrent use of anticholinergic and anti-dementia drugs (ADDs) in older adults with dementia. Methods: A PRISMA-informed systematic review was conducted employing Ovid MEDLINE, Embase and PsycINFO from January 2010 to April 2026. Observational studies were eligible if they included older adults with dementia and reported concurrent exposure to at least one anticholinergic medicine and an ADD, defined as AChEIs and\/or memantine. Study quality was appraised using the Newcastle\u2013Ottawa Scale. Results: Twenty-eight studies were included, spanning community, outpatient memory-clinic, acute hospital, long-term care and population-based settings. Two distinct exposure constructs were identified: (1) temporal co-prescribing and (2) cumulative anticholinergic burden among ADD users. Reported prevalence varied markedly according to the exposure definition and setting. Concurrent use was lowest in studies limited to bladder antimuscarinic overlap, generally around 5\u201313%,but increased to 20\u201345% when broader anticholinergic definitions were used. In long-term care and institutional cohorts, concurrent exposure reached 61\u201367%. Recurring predictors included polypharmacy, fragmented care or multiple prescribers, urinary symptoms, behavioural and psychological symptoms of dementia, Parkinson\u2019s disease and non-geriatric prescribing. One large population-based study reported that high anticholinergic burden was associated with treatment modification of AChEIs (aHR 1.12), delirium (aHR 1.52), and two-year mortality (aHR 1.23). Additional studies reported associations with longer hospital stays or readmission. Conclusions: Concurrent use of anticholinergic medicines and ADDs is a common, clinically important and potentially modifiable medication-safety problem in dementia care.<\/jats:p>","DOI":"10.3390\/medsci14040426","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:53:26Z","timestamp":1784901206000},"page":"426","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concurrent Use of Anticholinergic and Antidementia Medicines in Older Adults with Dementia: A Systematic Review of Prevalence, Predictors and Clinical Outcomes"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2097-6671","authenticated-orcid":false,"given":"Zahraa","family":"Falfaly","sequence":"first","affiliation":[{"name":"School of Pharmacy and Pharmacology, Health, University of Tasmania, P.O. Box 845, Hobart, TAS 7006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6764-3882","authenticated-orcid":false,"given":"Gregory M.","family":"Peterson","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmacology, Health, University of Tasmania, P.O. Box 845, Hobart, TAS 7006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3028-6949","authenticated-orcid":false,"given":"Woldesellassie M.","family":"Bezabhe","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmacology, Health, University of Tasmania, P.O. Box 845, Hobart, TAS 7006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9131-7465","authenticated-orcid":false,"given":"Mohammed S.","family":"Salahudeen","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmacology, Health, University of Tasmania, P.O. Box 845, Hobart, TAS 7006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_2","unstructured":"GBD 2019 Dementia Forecasting Collaborators (2022). Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the global burden of disease study 2019. Lancet Public Health, 7, e105\u2013e125."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/1061186X.2018.1474361","article-title":"Drug development for alzheimer\u2019s disease: Review","volume":"27","author":"Lao","year":"2019","journal-title":"J. Drug Target."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Stanciu, G.D., Luca, A., Rusu, R.N., Bild, V., Beschea Chiriac, S.I., Solcan, C., Bild, W., and Ababei, D.C. (2019). Alzheimer\u2019s disease pharmacotherapy in relation to cholinergic system involvement. Biomolecules, 10.","DOI":"10.3390\/biom10010040"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1093\/brain\/awac096","article-title":"Reimagining cholinergic therapy for alzheimer\u2019s disease","volume":"145","author":"Giacobini","year":"2022","journal-title":"Brain"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12779\/dnd.2025.24.1.1","article-title":"Clinical practice guidelines for dementia: Recommendations for cholinesterase inhibitors and memantine","volume":"24","author":"Kim","year":"2025","journal-title":"Dement. Neurocogn. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1111\/bcp.13976","article-title":"Anticholinergic medicines use among older adults before and after initiating dementia medicines","volume":"85","author":"Narayan","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000454948","article-title":"Comedication and treatment length in users of acetylcholinesterase inhibitors","volume":"7","author":"Hjellvik","year":"2017","journal-title":"Dement. Geriatr. Cogn. Disord. Extra"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Jenraumjit, R., Chinwong, S., Chinwong, D., Kanjanarach, T., Kshetradat, T., Wongpakaran, T., and Wongpakaran, N. (2020). Anticholinergics and benzodiazepines on cognitive impairment among elderly with alzheimer\u2019s disease: A 1 year follow-up study. BMC Res. Notes, 13.","DOI":"10.1186\/s13104-019-4874-z"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-\u00c1lvarez, J., Sevilla-Llewellyn-Jones, J., and Ag\u00fcera-Ortiz, L. (2019). Anticholinergic drugs in geriatric psychopharmacology. Front. Neurosci., 13.","DOI":"10.3389\/fnins.2019.01309"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40264-024-01506-5","article-title":"Drug-induced cognitive impairment","volume":"48","author":"Reimers","year":"2025","journal-title":"Drug Saf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/WAD.0000000000000370","article-title":"Anticholinergic use among the elderly with alzheimer disease in south korea: A population-based study","volume":"34","author":"Joung","year":"2020","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/ageing\/afr102","article-title":"The impact of anticholinergic burden in alzheimer\u2019s dementia-the laser-ad study","volume":"40","author":"Fox","year":"2011","journal-title":"Age Ageing"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/2042098616658399","article-title":"Anticholinergic medication use and dementia: Latest evidence and clinical implications","volume":"7","author":"Gray","year":"2016","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kiesel, E.K., Hopf, Y.M., and Drey, M. (2018). An anticholinergic burden score for german prescribers: Score development. BMC Geriatr., 18.","DOI":"10.1186\/s12877-018-0929-6"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Salahudeen, M.S., Duffull, S.B., and Nishtala, P.S. (2015). Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: A systematic review. BMC Geriatr., 15.","DOI":"10.1186\/s12877-015-0029-9"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jamda.2020.04.019","article-title":"Anticholinergic drug burden and delirium: A systematic review","volume":"22","author":"Egberts","year":"2021","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Crispo, J.A., Willis, A.W., Thibault, D.P., Fortin, Y., Hays, H.D., McNair, D.S., Bjerre, L.M., Kohen, D.E., Perez-Lloret, S., and Mattison, D.R. (2016). Associations between anticholinergic burden and adverse health outcomes in parkinson disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150621"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s41999-023-00824-8","article-title":"European position paper on polypharmacy and fall-risk-increasing drugs recommendations in the world guidelines for falls prevention and management: Implications and implementation","volume":"14","author":"Seppala","year":"2023","journal-title":"Eur. Geriatr. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bartolone, S.N., Sharma, P., Chancellor, M.B., and Lamb, L.E. (2021). Urinary incontinence and alzheimer\u2019s disease: Insights from patients and preclinical models. Front. Aging Neurosci., 13.","DOI":"10.3389\/fnagi.2021.777819"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"(2023). By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American geriatrics society 2023 updated ags beers criteria\u00ae for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc., 71, 2052\u20132081.","DOI":"10.1111\/jgs.18372"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s41999-023-00812-y","article-title":"Correction: Stopp\/start criteria for potentially inappropriate prescribing in older people: Version 3","volume":"14","author":"Cherubini","year":"2023","journal-title":"Eur. Geriatr. Med."},{"key":"ref_24","unstructured":"National Institute for Health and Care Excellence (2018). Guidelines. Dementia: Assessment, Management and Support for People Living with Dementia and Their Carers, National Institute for Health and Care Excellence (NICE)."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Watanabe, J.H., and Hoang, T. (2023). Exploring concomitant acetylcholinesterase inhibitor and overactive bladder anticholinergic use and risk of hospitalization in medicare and dual-eligible medicare-medicaid populations in a historic database. Pharmacy, 11.","DOI":"10.3390\/pharmacy11050140"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Trenaman, S.C., Bowles, S.K., Kirkland, S., and Andrew, M.K. (2021). An examination of three prescribing cascades in a cohort of older adults with dementia. BMC Geriatr., 21.","DOI":"10.1186\/s12877-021-02246-2"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40801-020-00181-z","article-title":"Patterns of potentially inappropriate bladder antimuscarinic use in people with dementia: A retrospective cohort study","volume":"7","author":"Green","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Elliott, T., Eckmann, L., and Moga, D.C. (2021). Case report: The complexities of managing medications and the importance of deprescribing anticholinergics in older adults. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.584667"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1002\/alz.12808","article-title":"Effect of collaborative dementia care on potentially inappropriate medication use: Outcomes from the care ecosystem randomized clinical trial","volume":"19","author":"Liu","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e01008","DOI":"10.1002\/prp2.1008","article-title":"Prescribing cascades in community-dwelling adults: A systematic review","volume":"10","author":"Doherty","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/jgs.14657","article-title":"Making a bad diagnosis worse? Suspect drug management of urinary incontinence in persons with dementia","volume":"65","author":"Carnahan","year":"2017","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/JCP.0000000000000133","article-title":"Concomitant use of acetylcholine esterase inhibitors and urinary antispasmodics among finnish community-dwelling persons with alzheimer disease","volume":"34","author":"Taipale","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The prisma 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00228-020-02994-x","article-title":"Quality of anticholinergic burden scales and their impact on clinical outcomes: A systematic review","volume":"77","author":"Lisibach","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gualdi-Russo, E., and Zaccagni, L. (2026). The Newcastle\u2013Ottawa Scale for Assessing the Quality of Studies in Systematic Reviews. Publications, 14.","DOI":"10.3390\/publications14010004"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (swim) in systematic reviews: Reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40266-024-01103-2","article-title":"Cumulative anticholinergic burden and its predictors among older adults with alzheimer\u2019s disease initiating cholinesterase inhibitors","volume":"41","author":"Talwar","year":"2024","journal-title":"Drugs Aging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/j.1532-5415.2011.03654.x","article-title":"Concomitant use of cholinesterase inhibitors and anticholinergics: Prevalence and outcomes","volume":"59","author":"Boudreau","year":"2011","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4140\/TCP.n.2024.449","article-title":"Examining the impact of anticholinergic burden on hospitalized older people receiving concomitant cholinesterase inhibitors","volume":"39","author":"Guan","year":"2024","journal-title":"Sr. Care Pharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jgs.18066","article-title":"Anticholinergic co-prescribing in nursing home residents using cholinesterase inhibitors: Potential deprescribing cascade","volume":"71","author":"Gromek","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamaneurol.2018.2820","article-title":"Patterns of dementia treatment and frank prescribing errors in older adults with parkinson disease","volume":"76","author":"Mantri","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/psyg.12267","article-title":"Simultaneous usage of dementia medications and anticholinergics among asians and pacific islanders","volume":"17","author":"Schultz","year":"2017","journal-title":"Psychogeriatr. Off. J. Jpn. Psychogeriatr. Soc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/jgs.14498","article-title":"Use of bladder antimuscarinics in older adults with impaired cognition","volume":"65","author":"Green","year":"2017","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40266-014-0227-8","article-title":"Use of drugs with anticholinergic properties among nursing home residents with dementia: A national analysis of medicare beneficiaries from 2007 to 2008","volume":"32","author":"Palmer","year":"2015","journal-title":"Drugs Aging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/jgs.14034","article-title":"Anticholinergic drug burden in persons with dementia taking a cholinesterase inhibitor: The effect of multiple physicians","volume":"64","author":"Fischer","year":"2016","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40266-019-00690-9","article-title":"Sex differences in the prevalent use of oral formulations of cholinesterase inhibitors in older adults with dementia","volume":"36","author":"Zhu","year":"2019","journal-title":"Drugs Aging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/ggi.13748","article-title":"Potentially inappropriate prescriptions of anticholinergics drugs in alzheimer\u2019s disease patients","volume":"19","year":"2019","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000546708","article-title":"Pharmaceutical treatment of people with dementia during the SARS-CoV-2 pandemic in germany: Polypharmacy, anticholinergic medication, and antidementia medication","volume":"15","author":"Floto","year":"2025","journal-title":"Dement. Geriatr. Cogn. Disord. Extra"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2165\/11318010-000000000-00000","article-title":"Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with alzheimer\u2019s disease: A 2-year prospective, multicentre, cohort study","volume":"24","author":"Gardette","year":"2010","journal-title":"CNS Drugs"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00228-015-1869-0","article-title":"Atropinic burden of prescriptions forms in patients with alzheimer disease: A cross-sectional study in a french pharmacovigilance database","volume":"71","author":"Montastruc","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3233\/JAD-151177","article-title":"Potentially inappropriate prescribing among people with dementia in primary care: A retrospective cross-sectional study using the enhanced prescribing database","volume":"52","author":"Barry","year":"2016","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Hook, A., Randall, J.L., Grubb, C.M., Ellis, N., Wellington, J., Hemmad, A., Zerdelis, A., Winnett, A.R.D., Geers, B.D.W., and Sykes, B. (2022). Anti-cholinergic drug burden in patients with dementia increases after hospital admission: A multicentre cross-sectional study. BMC Geriatr., 22.","DOI":"10.1186\/s12877-022-03235-9"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bcpt.13184","article-title":"Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: A population-based study","volume":"124","author":"Ah","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Baik, D., Yu, Y.M., Jung, S.-Y., and Kang, H.-Y. (2022). Prevalence and patterns of the concurrent use of anticholinergics for the motor symptoms of parkinson\u2019s disease and acetylcholinesterase inhibitors in parkinson\u2019s disease patients with dementia: A cross-sectional study using korea national health insurance claims data. BMC Geriatr., 22.","DOI":"10.1186\/s12877-022-03296-w"},{"key":"ref_55","first-page":"133","article-title":"A prescription survey about combined use of acetylcholinesterase inhibitors and anticholinergic medicines in the dementia outpatient using electronic medication history data from community pharmacies","volume":"4","author":"Kurata","year":"2015","journal-title":"Integr. Pharm. Res. Pract."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/1533317518768999","article-title":"Use of potentially inappropriate medications in people with dementia in vietnam and its associated factors","volume":"33","author":"Nguyen","year":"2018","journal-title":"Am. J. Alzheimer\u2019s Dis. Other Dement."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40801-015-0012-y","article-title":"Use of medicines with anticholinergic and sedative effect before and after initiation of anti-dementia medications","volume":"2","author":"Gadzhanova","year":"2015","journal-title":"Drugs Real World Outcomes"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40266-015-0332-3","article-title":"Potentially inappropriate medications and anticholinergic burden in older people attending memory clinics in australia","volume":"33","author":"Cross","year":"2016","journal-title":"Drugs Aging"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4140\/TCP.n.2017.764","article-title":"Determination of anticholinergic medication use in patients prescribed medications for the treatment of dementia","volume":"32","author":"Ellard","year":"2017","journal-title":"Consult. Pharm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40266-017-0510-6","article-title":"Brain over bladder: A systematic review of dual cholinesterase inhibitor and urinary anticholinergic use","volume":"35","author":"Triantafylidis","year":"2018","journal-title":"Drugs Aging"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"afad176","DOI":"10.1093\/ageing\/afad176","article-title":"Interventions for reducing anticholinergic medication burden in older adults-a systematic review and meta-analysis","volume":"52","author":"Braithwaite","year":"2023","journal-title":"Age Ageing"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jamda.2019.06.001","article-title":"Interventions to reduce anticholinergic burden in adults aged 65 and older: A systematic review","volume":"21","author":"Nakham","year":"2020","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1080\/14740338.2020.1811227","article-title":"Anticholinergic medications and risk of dementia in older adults: Where are we now?","volume":"19","author":"Chatterjee","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_64","first-page":"CD015405","article-title":"Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment","volume":"12","author":"Alharthi","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_65","first-page":"408","article-title":"Pharmacist-driven deprescribing to reduce anticholinergic burden in veterans with dementia","volume":"41","author":"Deglow","year":"2024","journal-title":"Fed. Pract."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Kable, A., Fraser, S., Fullerton, A., Hullick, C., Palazzi, K., Oldmeadow, C., Pond, C.D., Searles, A., Ling, R., and Bruce, R. (2023). Evaluation of the effect of a safe medication strategy on potentially inappropriate medications, polypharmacy and anticholinergic burden for people with dementia: An intervention study. Healthcare, 11.","DOI":"10.3390\/healthcare11202771"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e70103","DOI":"10.1111\/bcpt.70103","article-title":"Deprescribing anticholinergic medications in hospitalised older adults: A systematic review","volume":"137","author":"Griffiths","year":"2025","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s10916-022-01808-0","article-title":"Chronic-pharma: New platform for chronic patients pharmacotherapy optimization","volume":"46","year":"2022","journal-title":"J. Med. Syst."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/17512433.2025.2546142","article-title":"Rethinking anticholinergic burden in older adults: Innovative approaches to detection and management","volume":"18","author":"Phutietsile","year":"2025","journal-title":"Expert Rev. Clin. Pharmacol."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/4\/426\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:07:45Z","timestamp":1784902065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/4\/426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":69,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["medsci14040426"],"URL":"https:\/\/doi.org\/10.3390\/medsci14040426","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}